Alkermes Looks To Fill Cancer Treatment Gaps With New Immune Pathways A conversation with Craig Hopkinson

Patients are at the center of what we do, and we are united in our mission to pursue great science with deep compassion as we strive to positively impact the lives of those affected by cancer.

In this PharmaVoice interview, Alkermes’ Chief Medical Officer, Craig Hopkinson, MD, discusses our ongoing research for difficult-to-treat cancers and the development program of our #immunooncology candidate: https://bit.ly/3yU9CTh

View additional multimedia and more ESG storytelling from Alkermes on 3blmedia.com